Explore 3 Stock Ideas & Industry Insights Download Free Report

small-cap

CorMedix Therapeutics: Portfolio Diversification Supports Growth Amid Reimbursement Pressure

Nov 19, 2026 | Team Kalkine
CorMedix Therapeutics: Portfolio Diversification Supports Growth Amid Reimbursement Pressure
Image source: shutterstock

  • CRMD:NASDAQ
  • Investment Type
    Small-Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

CorMedix Inc

CorMedix Inc (NASDAQ: CRMD) is a biopharmaceutical company focused on developing and commercializing therapies for life-threatening conditions. Its lead product, DefenCath, is an antimicrobial catheter lock solution that reduces catheter-related bloodstream infections in adults with kidney failure receiving chronic hemodialysis through a central venous catheter. Its commercial portfolio also includes anti-infective therapies MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA and KIMYRSA, alongside TOPROL-XL.

Financial Performance and Earnings Quality


Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…